Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | HMGCR | P04035 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3457854 | 0.84 | LMNA (0.38) | MEN1LMNAHPGDTSHRBLM | |
| SCHEMBL28777677 | 0.83 | TSHR (0.44) | MEN1LMNAHPGDTSHRBLM | |
| SCHEMBL10488413 | 0.79 | MEN1 (0.41) | MEN1LMNAHPGDTSHRBLM | |
| SCHEMBL10889136 | 0.74 | CYP1A2 (0.32) | CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL2710380 | 0.73 | HMGCR (0.38) | MEN1LMNAHPGDTSHRBLM | |
| SCHEMBL433467 | 0.72 | SMPD1 (0.43) | LMNABLMTDP1 | |
| SCHEMBL7597273 | 0.71 | PPARD (0.52) | MEN1LMNAHPGDTSHRBLM | |
| SCHEMBL2801406 | 0.70 | — | — | |
| SCHEMBL37980 | 0.70 | — | — | |
| SCHEMBL17139703 | 0.69 | TSHR (0.39) | MEN1LMNAHPGDTSHRBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030262-B2 | 3-Amino-2-hydroxyalkanoic acids and their prodrugs | ABBOTT LABORATORIES (US) | 2006-04-18 | — | — | US | disclosed |
| EP-1546087-A1 | 3-AMINO-2-HRYDROXYALKANOIC ACIDS AND THEIR PRODRUGS | Abbott Laboratories (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20040122098-A1 | 3-Amino-2-hydroxyalkanoic acids and their prodrugs | ABBVIE INC. | 2004-06-24 | — | — | US | disclosed |
| WO-2004013085-A1 | 3-AMINO-2-HRYDROXYALKANOIC ACIDS AND THEIR PRODRUGS | ABBOTT LABORATORIES (US) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122098-A1 | 3-Amino-2-hydroxyalkanoic acids and their prodrugs | HDGF, HCAR2, HCAR3 | MEN1 4205/4885LMNA 3395/4885HPGD 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.